Zymeworks Inc. operates in the biopharmaceutical space with a core asset, zanidatamab (marketed as Ziihera), licensed to Jazz Pharmaceuticals and BeOne Medicines. The company has leveraged licensing royalties through a $250 million funding deal with Royalty Pharma, selling 30% of future royalties but retaining milestone payments and majority royalty rights. Despite operating losses and negative cash flow, Zymeworks’ balance sheet remains strong with a high current ratio supported by significant current assets. Positive phase 3 clinical data bolster growth prospects, though execution risks persist due to the inherent uncertainties in drug development and regulatory approvals. The company’s share repurchase program highlights confidence in capital allocation despite ongoing losses.